A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
A pivotal week for prediction markets saw Coinbase partner with Kalshi to offer event contracts nationwide, while the CFTC moved to establish clearer regulatory standards. Meanwhile, traders sharply increased bets on a potential U.S. government shutdown.
Despite significant institutional purchases and regulatory progress, Bitcoin continues to drift lower, leading analysts and investors to question what price level will finally stem the tide.
As speculation intensifies over a potential acquisition of Warner Bros. Discovery by Netflix, short sellers are rapidly retreating from the stock, signaling market confidence in both the deal's completion and regulatory approval.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
Canadian National CEO Tracy Robinson has delivered a stark assessment of the proposed Union Pacific-Norfolk Southern merger, stating the railroads have "a long way to go" to satisfy regulatory concerns. In CN's earnings call, she criticized the application for failing to address competitive harms and warned of impacts on shippers, setting the stage for a contentious review process.
Reports suggest Elon Musk is exploring a merger between Tesla and SpaceX as the EV maker pivots to AI, while Chinese automakers gain record European market share and regulatory battles intensify.
In a landmark day for digital asset policy, U.S. regulators unveiled a coordinated initiative while a key Senate committee advanced market structure legislation, signaling a potential end to years of regulatory uncertainty.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
In a major policy shift, the CFTC under new Chairman Michael Selig is drafting a comprehensive rulebook for event contracts, aiming to bring regulatory certainty to the fast-growing prediction market industry while fostering 'permissionless innovation.'
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Ondas Holdings' flagship Optimus drone system has received the Defense Contract Management Agency's critical 'Blue List' certification, clearing it for broader U.S. defense and national security deployment. The milestone has ignited a surge in the company's stock while prompting analysts to scrutinize its long-term path to converting regulatory approval into sustainable revenue.
Robinhood Markets is making a bold two-pronged move, expanding its tokenized stock offerings while positioning itself as a key retail gateway for SpaceX's anticipated IPO. This strategy underscores its ambition to democratize high-profile investments but also intensifies scrutiny on its regulatory risks and valuation.
Kevin Warsh, a leading candidate for Federal Reserve Chair, has historically framed Bitcoin not as a threat but as a crucial policy signal. His past comments labeling it 'the new gold' for younger investors stand in stark contrast to the cryptocurrency's recent 3% decline, highlighting the volatile intersection of regulatory sentiment and digital asset markets.
After a period of Bitcoin dominance, a confluence of technological maturity, shifting institutional narratives, and regulatory clarity could propel Ethereum back into the spotlight. Analysts point to its foundational role in decentralized finance and a series of upcoming catalysts as reasons for a potential breakout year.
NVIDIA's CEO Jensen Huang indicates that Chinese regulatory approval for the sale of its flagship H200 AI chip is still pending, amid high demand from major tech firms and ongoing U.S.-China tech tensions.
In a cafe in eastern Turkey, Iranian exiles gather, their eyes fixed on news from home. As a new wave of protests meets a severe crackdown, those who fled earlier unrest watch, wait, and voice a desperate mix of anguish, anger, and fragile hope.
